Evaluation of a Large Renal Mass Using 99mTc-MIBI SPECT/CT in a Patient With Chronic Kidney Disease

Steven Rowe, Michael Gorin, Mehrbod Som Som Javadi, Mohamad E Allaf

Research output: Contribution to journalArticle

Abstract

The differentiation of benign and indolent renal masses from aggressive tumor histologies cannot be reliably performed by CT or MRI. Additionally, renal mass biopsy risks complications and has a nondiagnostic rate of 10% to 20%. Tc-MIBI SPECT/CT has been shown to allow for the accurate differentiation of benign renal oncocytomas and hybrid oncocytic/chormophobe tumors from other more aggressive renal tumor types. We present the case of an 84-year-old man with chronic kidney disease and an 11.2-cm renal mass. Results of his Tc-MIBI SPECT/CT allowed avoidance of a radical nephrectomy.

Original languageEnglish (US)
Pages (from-to)e166-e167
JournalClinical Nuclear Medicine
Volume42
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Chronic Renal Insufficiency
Technetium Tc 99m Sestamibi
Kidney
Neoplasms
Nephrectomy
Histology
Biopsy
Single Photon Emission Computed Tomography Computed Tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Evaluation of a Large Renal Mass Using 99mTc-MIBI SPECT/CT in a Patient With Chronic Kidney Disease. / Rowe, Steven; Gorin, Michael; Javadi, Mehrbod Som Som; Allaf, Mohamad E.

In: Clinical Nuclear Medicine, Vol. 42, No. 3, 01.03.2017, p. e166-e167.

Research output: Contribution to journalArticle

@article{915c081223e2456a9cceb704b9664dbb,
title = "Evaluation of a Large Renal Mass Using 99mTc-MIBI SPECT/CT in a Patient With Chronic Kidney Disease",
abstract = "The differentiation of benign and indolent renal masses from aggressive tumor histologies cannot be reliably performed by CT or MRI. Additionally, renal mass biopsy risks complications and has a nondiagnostic rate of 10{\%} to 20{\%}. Tc-MIBI SPECT/CT has been shown to allow for the accurate differentiation of benign renal oncocytomas and hybrid oncocytic/chormophobe tumors from other more aggressive renal tumor types. We present the case of an 84-year-old man with chronic kidney disease and an 11.2-cm renal mass. Results of his Tc-MIBI SPECT/CT allowed avoidance of a radical nephrectomy.",
author = "Steven Rowe and Michael Gorin and Javadi, {Mehrbod Som Som} and Allaf, {Mohamad E}",
year = "2017",
month = "3",
day = "1",
doi = "10.1097/RLU.0000000000001533",
language = "English (US)",
volume = "42",
pages = "e166--e167",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Evaluation of a Large Renal Mass Using 99mTc-MIBI SPECT/CT in a Patient With Chronic Kidney Disease

AU - Rowe, Steven

AU - Gorin, Michael

AU - Javadi, Mehrbod Som Som

AU - Allaf, Mohamad E

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The differentiation of benign and indolent renal masses from aggressive tumor histologies cannot be reliably performed by CT or MRI. Additionally, renal mass biopsy risks complications and has a nondiagnostic rate of 10% to 20%. Tc-MIBI SPECT/CT has been shown to allow for the accurate differentiation of benign renal oncocytomas and hybrid oncocytic/chormophobe tumors from other more aggressive renal tumor types. We present the case of an 84-year-old man with chronic kidney disease and an 11.2-cm renal mass. Results of his Tc-MIBI SPECT/CT allowed avoidance of a radical nephrectomy.

AB - The differentiation of benign and indolent renal masses from aggressive tumor histologies cannot be reliably performed by CT or MRI. Additionally, renal mass biopsy risks complications and has a nondiagnostic rate of 10% to 20%. Tc-MIBI SPECT/CT has been shown to allow for the accurate differentiation of benign renal oncocytomas and hybrid oncocytic/chormophobe tumors from other more aggressive renal tumor types. We present the case of an 84-year-old man with chronic kidney disease and an 11.2-cm renal mass. Results of his Tc-MIBI SPECT/CT allowed avoidance of a radical nephrectomy.

UR - http://www.scopus.com/inward/record.url?scp=85028282398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028282398&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001533

DO - 10.1097/RLU.0000000000001533

M3 - Article

VL - 42

SP - e166-e167

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 3

ER -